Stepping down to as-needed ICS/FABA maintained asthma stability while significantly reducing steroid exposure in individuals ...

Recommended management of asthma, including appropriate diagnostic steps and use of fractional exhaled nitric oxide (FeNO) in ...

Currently, systemic corticosteroids are recommended to treat acute exacerbations of asthma, because they prevent the progression of exacerbations, decrease the hospitalization rate, reduce morbidity, ...

Albuterol/budesonide is a short-acting beta2-agonist and inhaled corticosteroid asthma rescue therapy approved under the brand name Airsupra.

Background We aimed to evaluate the efficacy and safety of single combined fast-acting beta2-agonist/inhaled corticosteroid (FABA/ICS) inhaler only used as needed in people with mild asthma. Methods ...

If these trials confirm the findings, benralizumab could become the first new therapy approved for eosinophilic exacerbations of asthma and COPD in over 50 years.

There may be a more effective treatment for severe asthma and chronic obstructive pulmonary disease (COPD) attacks than that used as the standard of care for 50 years, according to a recent study.

It is currently used for the treatment of severe asthma. The ABRA trial has found a single dose can be more effective when injected at the point of exacerbation compared to steroid tablets.

The following is a summary of “Airway proteomics reveals broad residual anti-inflammatory effects of prednisolone in mepolizumab-treated asthma,” published in the August 2024 issue of Allergy and ...

Introduction The aim of this open-label trial is to examine whether a single dose of dexamethasone is non-inferior to a 3-day course of prednisolone in the treatment of exacerbations of asthma in ...

Introduction Oral corticosteroids are the cornerstone of acute asthma management in the emergency department. Recent evidence has raised doubts about the efficacy of this treatment in preschool-aged ...

The 208 patients were randomly assigned to taper their high-dose inhaled steroid by varying amounts over 32 weeks, followed by a 16-week maintenance period. Approximately 90% of patients experienced ...